Sarcoma Clinical Trials

A listing of Sarcoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
FHD-609 in Subjects With Advanced Synovial Sarcoma

activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma.

  • 0 views
  • 21 Jul, 2021
  • 6 locations
A Study to Evaluate Direct Wire Pacing (DWP) for Measuring Fractional Flow Reserve (FFR)

indications. All subjects requiring on a clinical basis a pressure wire assessment of coronary artery stenosis(es) will be eligible to take part in the study.

  • 0 views
  • 31 Jul, 2021
  • 1 location
IBI188 Combination Therapy in Solid Tumors

A Phase Ib study aim to explore the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

carboplatin
measurable disease
gm-csf
colony stimulating factor
  • 0 views
  • 28 Jul, 2021
  • 1 location
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.

cancer chemotherapy
carboplatin
measurable disease
pembrolizumab
etoposide
  • 0 views
  • 31 Jul, 2021
  • 1 location
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents

measurable disease
pembrolizumab
  • 0 views
  • 31 Jul, 2021
A Study Evaluating the Safety Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

This open-label, First-into-Human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK) and early efficacy of AVA6000, a FAP-activated pro-drug of doxorubicin, in patients with locally advanced and/or metastatic solid tumours. In Phase Ia, using a 3+3 design, escalating doses of AVA6000 will be administered to patients with a range …

  • 0 views
  • 31 Jul, 2021
  • 1 location
Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors

Primary Objective: To assess safety of eltrombopag in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Secondary Objectives: To assess the efficacy of eltrombopag in increasing platelet count up to 2 weeks after completion of chemotherapy in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Hypothesis: The hypothesis …

  • 0 views
  • 30 Jul, 2021
  • 1 location
Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53

syndrome or family member of carrier TP53. Patients with only other types of breast cancer such as sarcoma and phyllodes tumor were excluded from the analysis.

TP53
invasive carcinoma
carcinoma
  • 0 views
  • 30 Jul, 2021
  • 1 location